Cargando…
Clinical effectiveness of molnupiravir in patients with COVID-19 undergoing haemodialysis
BACKGROUND: Molnupiravir is an essential oral antiviral agent against coronavirus disease 2019 (COVID-19); however, its real-world effectiveness has not been evaluated in patients undergoing haemodialysis (HD). METHODS: This multi-centre retrospective study, involving 225 patients undergoing HD with...
Autores principales: | Chang, Yi-Chin, Chen, Yi-Chun, Huang, Chiang-Chi, Fu, Chung-Ming, Lee, Yueh-Ting, Wu, Po-Jung, Lee, Wen-Chin, Lee, Chien-Te, Liao, Shang-Chih, Tsai, Kai-Fan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148756/ https://www.ncbi.nlm.nih.gov/pubmed/37127127 http://dx.doi.org/10.1016/j.ijantimicag.2023.106834 |
Ejemplares similares
-
Real-World Effectiveness of SARS-CoV-2 Vaccine Booster in Hemodialysis Patients with COVID-19 Receiving Molnupiravir
por: Chen, Po-Chun, et al.
Publicado: (2023) -
Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
por: Lee, Ching-Chi, et al.
Publicado: (2021) -
Epicardial adipose tissue thickness is not associated with adverse cardiovascular events in patients undergoing haemodialysis
por: Chen, Ying-Chih, et al.
Publicado: (2020) -
Gelsolin and Progression of Aortic Arch Calcification in Chronic Hemodialysis Patients
por: Chiou, Terry Ting-Yu, et al.
Publicado: (2016) -
The first case of Francisella novicida infection in Taiwan: bacteraemic pneumonia in a haemodialysis adult
por: Jan, Hao-En, et al.
Publicado: (2022)